EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study

Kunihiro Odagiri, Yoshihisa Mimura, Taku Naiki iD, Yoshihiko Tasaki, Yosuke Sugiyama, Aya Naiki-Ito iD, Toshiki Etani, Takashi Nagai, Toshiharu Morikawa, Nobuhiko Shimizu, Maria Aoki, Masakazu Gonda und 2 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf167 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Kunihiro Odagiri und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cachexia. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nitto Foundation, CASIO SCIENCE PROMOTION FOUNDATION, Foundation for Promotion of Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer cachexia reduces chemotherapy efficacy in patients with metastatic urothelial carcinoma (mUC). Anamorelin improves cancer cachexia by increasing serum insulin-like growth factor 1 (IGF-1). The aim of this study was to evaluate the efficacy and safety of anamorelin in patients with mUC.

Methods

A total of 38 patients with mUC who received platinum-based chemotherapy were enrolled in an interventional prospective study. Patients were randomized to anamorelin (Ana; n = 20) or control (n = 18) groups. The primary endpoint was the change in prealbumin. Secondary endpoints were changes in albumin, IGF-1, body weight, skeletal muscle mass index (SMI), interleukin-6 (IL-6) and median overall survival (mOS).

Results

Changes in prealbumin, albumin, body weight, and SMI were similar between groups. Compared to control, serum IGF-1 levels in the anamorelin-treated group were higher after 1 week (P < .05). Changes in IGF-1 and SMI positively correlated in the anamorelin group (R = 0.61, P < .05). When the anamorelin group was divided into 2 groups by the median serum IGF-1 level after 1 week (Ana-IGF-1 high and Ana-IGF-1 low groups), the SMI in the latter group showed a decreased tendency (P = .14). The Ana-IGF-1 low group showed significantly higher IL-6 levels (P < .05) at baseline and significantly shorter mOS compared to the Ana-IGF-1 high group (P < .05). Treatment-related adverse events were comparable between the 2 groups (any grade: 100% vs 100%; grade ≥3: 88.9% vs 90.0%).

Conclusions

Anamorelin was well tolerated in patients with mUC. A higher serum IGF-1 level might be associated with anamorelin efficacy; however, a larger study is needed to confirm this.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCachexiaHumansMaleFemaleMiddle AgedAgedInsulin-Like Growth Factor INeoplasm MetastasisProspective StudiesInterleukin-6Treatment OutcomeAdult

Stichwörter der Autor:innen

anamorelincancer cachexiainsulin-like growth factor 1systemic chemotherapyurothelial carcinoma

Substanzen

Insulin-Like Growth Factor IInterleukin-6

Autor:innen und Institutionen

  • Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Urology, Nagoya City University West Medical Center, Nagoya, Japan.
  • Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

ORCID-Profile: Taku Naiki, Aya Naiki-Ito

Förderung

  • Nitto Foundation
  • CASIO SCIENCE PROMOTION FOUNDATION
  • Foundation for Promotion of Cancer Research
  • KAKENHI

Zitieren

APA

Odagiri, K., Mimura, Y., Naiki, T., Tasaki, Y., Sugiyama, Y., Naiki-Ito, A., Etani, T., Nagai, T., Morikawa, T., Shimizu, N., Aoki, M., Gonda, M., Yasui, T., & Furukawa-Hibi, Y. (2025). Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf167

Vancouver

Odagiri K, Mimura Y, Naiki T, Tasaki Y, Sugiyama Y, Naiki-Ito A, et al. Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf167

BibTeX
@article{Odagiri2025,
  author = {Odagiri, Kunihiro and Mimura, Yoshihisa and Naiki, Taku and Tasaki, Yoshihiko and Sugiyama, Yosuke and Naiki-Ito, Aya and Etani, Toshiki and Nagai, Takashi and Morikawa, Toshiharu and Shimizu, Nobuhiko and Aoki, Maria and Gonda, Masakazu and Yasui, Takahiro and Furukawa-Hibi, Yoko},
  title = {Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf167}
}
Kostenlos starten →